Fig. 4
From: Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects
Harnessing HLA-G in cancer immunotherapy. Numerous HLA-G-based therapeutics currently in preclinical or clinical stages could potentially be leveraged to target human cancers. Monoclonal antibodies and CAR-NK cells against HLA-G can restrain tumor growth. Anti-HLA-G antibody also serve as a favorable partner for chemotherapy, ICB, and targeted therapies, including CDKi, ERKi, AKTi, and angiogenesis inhibitors. Moreover, small-molecule inhibitors, miRNA mimics, and PROTACs may provide new opportunities for future applications of HLA-G. CAR-NK cells chimeric antigen receptor NK cells, ICB immune checkpoint blockade, CDKi CDK inhibitors, ERKi ERK inhibitors, AKTi AKT inhibitors, PROTACs proteolysis-targeting chimeras